PUBLISHER: The Business Research Company | PRODUCT CODE: 2035873
PUBLISHER: The Business Research Company | PRODUCT CODE: 2035873
Chitosan-based hemostasis management products are medical materials or devices that utilize chitosan, a natural biopolymer derived from chitin, to rapidly stop bleeding by promoting clot formation and platelet aggregation at the wound site. These products are widely used in surgical, emergency, and trauma care as effective alternatives or supplements to traditional hemostatic methods like gauze or pressure dressings.
The key product types of chitosan-based hemostasis management products include dressings, sponges, powders, and other variants. Dressings are chitosan-infused materials designed to promote rapid blood clotting and control bleeding in surgical or traumatic settings. Applications include surgical wounds, trauma, and other areas, serving hospitals, ambulatory surgical centers, and other end-users.
Tariffs on imported chitosan, biopolymer materials, and medical-grade manufacturing components are impacting the chitosan-based hemostasis management market by increasing production costs, particularly affecting dressings, sponges, and powder segments. Regions such as North America, Europe, and Asia-Pacific, which rely on imported raw materials and components, are most affected. While tariffs raise costs, they also encourage domestic production, stimulate local innovation in cost-efficient hemostatic products, and promote regional supply chain resilience, offering strategic advantages in the long term.
The chitosan-based hemostasis management products market research report is one of a series of new reports from The Business Research Company that provides chitosan-based hemostasis management products market statistics, including chitosan-based hemostasis management products industry global market size, regional shares, competitors with a chitosan-based hemostasis management products market share, detailed chitosan-based hemostasis management products market segments, market trends and opportunities, and any further data you may need to thrive in the chitosan-based hemostasis management products industry. This chitosan-based hemostasis management products market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The chitosan-based hemostasis management products market size has grown strongly in recent years. It will grow from $1.65 billion in 2025 to $1.81 billion in 2026 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to increasing use of traditional hemostatic materials, rising incidence of trauma and surgical procedures, growing awareness of rapid bleeding control, adoption of chitosan in medical applications, expansion of hospital and surgical infrastructure.
The chitosan-based hemostasis management products market size is expected to see strong growth in the next few years. It will grow to $2.64 billion in 2030 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to growing adoption of advanced hemostatic powders, rising demand for minimally invasive surgical solutions, increasing use in emergency and trauma care, expansion of product offerings in ambulatory surgical centers, growing focus on antimicrobial and biocompatible hemostatic solutions. Major trends in the forecast period include increasing adoption of chitosan-based hemostatic dressings, rising demand for absorbable hemostatic sponges, growing integration of sprayable and topical hemostatic powders, expansion of hemostatic sealants and bandages in trauma care, rising focus on antimicrobial and adhesive hemostatic products.
The rising incidence of traumatic injuries is anticipated to drive the expansion of the chitosan-based hemostasis management products market in the coming years. Traumatic injuries refer to bodily harm or damage resulting from sudden external forces, including accidents, falls, or violent events, which may impact tissues, organs, bones, or the nervous system. The growing occurrence of traumatic injuries is largely attributed to road traffic accidents, which represent a substantial share of severe injuries globally due to high vehicle density, overspeeding, and insufficient road safety measures. Chitosan-based hemostasis management products assist in managing traumatic injuries by quickly facilitating blood clot formation at the wound site, minimizing blood loss, and enabling faster stabilization compared to conventional gauze or pressure-only techniques. For instance, in October 2024, according to the Department of Health Alaska, a US-based government department, in 2023, about 3,373 individuals in Alaska sustained traumatic brain injuries (TBI). Therefore, the rising incidence of traumatic injuries is fueling the growth of the chitosan-based hemostasis management products market.
Leading companies operating in the chitosan-based hemostasis management products market are focusing on developing innovative products such as aerosolized chitosan hemostatic sprays to rapidly control bleeding and improve emergency trauma care. An aerosolized chitosan hemostatic spray is a medical product that administers chitosan in a fine mist directly to a wound, creating a rapid-acting barrier that helps control bleeding. For example, in April 2023, BC3 Technologies Inc., a US-based medical device company, obtained approval from the U.S. Food and Drug Administration (FDA) for BC3's SEAL Hemostatic Wound Spray, an aerosolized chitosan hemostatic spray developed to rapidly control bleeding. The spray establishes a physical barrier over wounds, supporting clot formation and enabling prompt management of severe arterial and traumatic bleeding. Following regulatory clearance, the product became available for use by first responders, military personnel, and emergency medical services, strengthening on-site hemorrhage control capabilities. This approval also enables BC3 Technologies to broaden its footprint in the trauma care and emergency medical device market.
The growing volume of surgical procedures is projected to accelerate the expansion of the chitosan-based hemostasis management products market in the foreseeable future. Surgical procedures refer to medically conducted operations that involve incisions, tissue manipulation, or removal to diagnose, treat, or repair injuries, diseases, or deformities. The surge in surgical procedures is primarily driven by the increasing prevalence of chronic diseases, as a larger patient population requires operative interventions to manage or address long-term health conditions. Chitosan-based hemostasis management products support surgical procedures by swiftly promoting clot formation at bleeding sites, thereby decreasing blood loss, reducing operative duration, and enhancing overall surgical outcomes. For example, according to the 2024 annual report of Intuitive Surgical Inc., a US-based medical device company, approximately 2,683,000 surgical procedures were performed using da Vinci surgical systems, compared to around 2,286,000 procedures in 2023 and 1,875,000 procedures in 2022, demonstrating consistent year-over-year growth in utilization. Therefore, the growing number of surgical procedures is propelling the growth of the chitosan-based hemostasis management products market.
Major companies operating in the chitosan-based hemostasis management products market are BenQ Materials Corporation, Core Scientific Creations Ltd, Advanced Medical Solutions Group plc, Ore-Medix LLC, Axio Biosolutions Pvt. Ltd., Marine Polymer Technologies Inc., Tri-Tech Forensics Inc, The Seaberg Company Inc, Tricol Biomedical Inc., Datsing Bio-Tech Co Ltd., Medtrade Products Ltd., Gelita Medical GmbH, HemCon Medical Technologies Inc, Hemostasis LLC, BC3 Technologies Inc, Omni-stat Medical Inc, MMC MedTech Co Ltd, Anhui Wound Solutions, ChitoTech Company, CoreLeader Biotech Co. Ltd.
North America was the largest region in the chitosan-based hemostasis management products market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chitosan-based hemostasis management products market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the chitosan-based hemostasis management products market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The chitosan-based hemostasis management products market consists of sales of chitohem powder, chitosponge, hemogauze hemostatic band aid, chitocell ultra-thin pads, and chitoclot gauze. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Chitosan-based Hemostasis Management Products Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses chitosan-based hemostasis management products market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for chitosan-based hemostasis management products ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The chitosan-based hemostasis management products market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.